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‘‘These, Gentlemen, are the opinions upon which I base my facts.’’
— Sir Winston Churchill
O
f the recent issues affecting the practice of cardiothoracic surgery, perhaps
none has affected or evoked more passionate debate (and angst) than the con-
troversy surrounding the use of the antifibrinolytic aprotinin (Trasylol, Bayer
Pharmaceuticals, West Haven, Conn). Aprotinin first appeared as a potent therapy for
pancreatitis; it soon became apparent that the antifibrinolytic properties of this serine
proteinase inhibitor could have a beneficial effect on postoperative bleeding in pa-
tients after cardiopulmonary bypass surgery. Cosgrove and colleagues,1 in a small,
randomized trial, confirmed the benefits of aprotinin in reducing postoperative chest
tube output and transfusion requirements, but they also noted a statistically nonsignif-
icant increase in Q-wave myocardial infarction (and in some cases graft thrombosis)
in the low-dose and high-dose aprotinin arms of their study. In 1993, the Food and
Drug Administration (FDA) approved aprotinin for use in patients undergoing coro-
nary artery bypass grafting (CABG), with subsequent changes in labeling in 1994 and
1998.
In 2006, Mangano and colleagues2 and Karkouti and colleagues3 published studies
that generated much controversy and prompted the FDA to convene an advisory com-
mittee meeting in September of 2006. Both studies were observational analyses of
prospectively collected data, and both used a statistical technique of propensity
matching. The expressed purpose of the advisory meeting was to elicit advice in re-
sponse to the studies’ findings that the use of aprotinin was associated with an in-
creased risk of adverse cardiovascular and renal events. In addition, the panel
wanted to reexamine data on anaphylactic reactions seen with the re-dosing of apro-
tinin. At the close of the meeting, the Committee provided the FDA with their conclu-
sions and recommendations (summarized in Table 1). The FDA then modified
aprotinin labeling in December of 2006, changing the approved indication for use
only in patients who are at increased risk for blood loss and blood transfusion in as-
sociation with cardiopulmonary bypass and CABG. In addition, changes were made
in labeling to handle the anaphylaxis issues.
The dust had barely settled when two pertinent events occurred. First, Mangano
and colleagues4 followed up with a second study, this one looking at long-term mor-
tality. Second, it was revealed that Bayer had not shared preliminary data from its own
observational clinical study (the so-called i3 Drug Safety Study) with the FDA before
the advisory committee meeting. The FDA reacted by convening a second advisory
committee meeting to review the data from the i3 Drug Safety Study and Mangano
and colleagues’ study. Before this meeting, FDA statisticians reviewed (for accuracy)
the datasets and results described by Mangano and colleagues, Karkouti and col-
leagues, and i3. At the completion of testimony and review of the data submitted,
the committee took 3 votes. In summary, the committee recommended 1) continued
marketing authorization (16 yes votes, 1 no, and 1 abstention); 2) that the findings of
i3 and Mangano and colleagues2,4 need not be described in product labeling (6 in
favor of including, 11 against, and 1 abstention); 3) additional clinical studies need
to be performed as a prerequisite of continued market authorization (unanimous).
In the meantime, investigators in Canada were reviewing their prospective data
from the BART (Blood conservation using antifibrinolytics: A randomized trial)
study. This study, overseen by the Ottawa Health Research Institute, involved 19
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 Trasylol increases the risk for renal dysfunction, but the data do not establish an increased risk for renal failure requiring dialysis.
 Hypersensitivity/anaphylactic reactions are known serious complications of the administration of aprotinin, and methods should be
sought to reduce their frequency and impact.
 Reduction in the frequency and amount of blood transfusion during CABG surgery remains an important benefit of the use of aprotinin.
 The benefit/risk ratio of aprotinin seems to be greatest in patients undergoing complex surgery or who have other risk factors for bleeding.
 The population in whom aprotinin is used should be more restrictive than currently approved.
CABG, Coronary artery bypass grafting.cardiac centers, with an expected enrollment of 2970 pa-
tients. There were 3 arms to this study; aprotinin and two 2
lysine analogs: tranexamic acid (Cyklokapron, Pharmacia
& UpJohn Inc, Somerset County, NJ) and epsilon-aminocap-
roic acid (Amicar, Xanodyne Pharmaceuticals, Newport,
Ky). The express purpose of this trial was to ‘‘definitively de-
termine if aprotinin’’ was superior to the other 2 antifibrino-
lytics in terms of decreasing postoperative bleeding,
decreasing blood and blood product use, and decreasing post-
operative morbidity and mortality. A review by the Data
Safety Monitoring Board (DSMB) after enrollment of 2163
patients revealed a nonstatistically significant trend toward
increased mortality in the aprotinin arm. Although no further
specific information is available at this time, it was noted that
the increase in mortality was approximately 2 per 100 pa-
tients, and that although aprotinin did decrease the amount
of serious bleeding, it was paradoxically associated with
more deaths due to hemorrhage. Bayer and the FDAwere no-
tified by the DSMB, a clinical advisory was issued, and sub-
sequently on November 5, 2007, Bayer announced
a moratorium on further marketing of aprotinin pending re-
view of the BART data.
In this issue, Pagano and colleagues5 add further data to
the ongoing debate. In summary, the authors find what has
always been the mainstay of aprotinin: significant reductions
in reoperation for bleeding and in transfusion requirements.
Where the data vary from Mangano and colleagues’ is in
the survival data. In the total group of patients receiving apro-
tinin, in-hospital mortality was not significantly different
from the control group (4.0% vs 3.5%), whereas the Euro-
SCORE in the aprotinin group was significantly higher.
Renal dysfunction also did not significantly differ between
the 2 groups.
The current study shares many of the same characteristics
with the BART study. Both studies were free from industry
support. The inclusion criteria were similar; BART included
reoperations for either CABG or aortic valve replacement
with a CABG, any mitral valve or multiple valve replacement
(including with CABG), aortic root replacements, and reop-
erations for adult congenital heart procedures. Unique exclu-
sion criteria in BART included patients unable to receive
blood products and those with previous exposure to aproti-
nin. Pagano and colleagues5 considered all adult patients
undergoing cardiac procedures (including primary revascu-The Journal of Thorlarization), excluding those requiring circulatory arrest, trans-
plantation, distal aortic surgery, and adult congenital surgery.
The number of patients in each study differed; BART was
designed to enroll 990 patients in each of the 3 arms, Pagano
and colleagues reviewed a total of 7836 patients (during
a 9-year period), of whom 3481 received aprotinin. In defer-
ence to Mangano and colleagues’ reports,2,4 the authors used
the same criteria for renal failure.
There are, however, potentially significant differences
other than study design (ie, randomized prospective multi-
center trial [BART] vs retrospective review of prospectively
acquired data from a single center). First, there seems to be
a difference in the administration of the aprotinin. The full-
dose Hammersmith protocol provides for a 2 million kalli-
krein inhibitor unit (KIU) bolus, 2 million KIU in the pump
prime, and 500,000 KIU/h infusion until chest closure.
Pagano and colleagues5 describe a similar dosing except
for the pump prime; they unexplainably used 1 million units.
BART described the infusion of 2 million units for 4 hours,
which matches the Hammersmith protocol during these 4
hours.
Second, as already alluded to, the inclusion criteria were
similar, but Pagano and colleagues5 also include primary
CABG. This can alter to some degree the risk stratification,
and therefore the post hoc analysis of risk. As seen in their
Table 1, this has the effect of altering the profile of the pa-
tients in each group. For example, the Canadian Cardiovascu-
lar Society class in the aprotinin group is lower, but the New
York Heart Association class is higher, reflecting that pa-
tients undergoing routine CABG did not necessarily receive
aprotinin (3391/4355 patients [78%] who did not receive
aprotinin underwent CABG compared with 1921/3481 pa-
tients [55%] who received aprotinin). Prediction of risk in
the study used the EuroSCORE, appropriate in this circum-
stance both for the robustness of the tool and for the patient
population. The multivariate analysis ultimately included
the variable EuroSCORE, along with diabetes, the year of
surgery, and the use of aprotinin. As the model was being fit-
ted, it seemed necessary to perform a log-transformation of
the score. As the authors point out, this can be statistically
justified using the Akaike Information Criterion. This crite-
rion takes into account both the goodness of fit and the num-
ber of parameters that have to be estimated to achieve this
particular degree of fit by imposing a ‘‘penalty’’ foracic and Cardiovascular Surgery c Volume 135, Number 3 493
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when the log EuroSCORE is taken into account, there
does not appear to be an increase risk of renal dysfunction,
need for dialysis, or mortality associated with the use of
aprotinin.
What happens if you move away from the model and look
at just the raw data? In Table 2, under ‘‘Other Cardiac Sur-
gery,’’ the patient mix now approaches that of BART,
although the patients were not randomized. The mortality
rates then appear equivalent (6.5% in the aprotinin group
and 6% in the non-aprotinin group). What is remarkable is
that, by report, the mortality rate in the aprotinin group is
approximately that seen in the BART aprotinin arm.
How then to judge this latest study in the face of BART?
We must first begin with facts. The Society of Thoracic Sur-
geons and the Society of Cardiovascular Anesthesiologists,
in a Joint Task Force, looked at the issue of blood transfusion
and cardiac surgery.6 Aprotinin itself was not the subject of
the clinical guideline, but the panel members were acutely
aware of issues brought up by the first FDA advisory commit-
tee. Despite the studies by Mangano and colleagues2,4 and
Karkouti and colleagues,3 the panel endorsed the use of apro-
tinin (as well as the other antifibrinolytics) with a Class I rec-
ommendation (level of evidence A). From an evidence-based
point of view, neither the BART study nor this current study
would seem to alter that recommendation, the former because
(at least at this point) statistical significance was not achieved,
the latter because the findings are similar to previous studies.
Most would agree that aprotinin does reduce the need for
transfusion, perhaps more so than the other antifibrinolytics.
Mounting evidence suggests that transfusion itself can lead
to a decrease survival in patients with cardiac disease,7 as
well as contribute to the development of renal failure.8 The
use of aprotinin in cardiac surgery is not a minor issue. In
the United States approximately 110,000 patients were ex-
posed to this drug in 2006, and 4.77 million exposures have
occurred worldwide since 1985. Alternatives do exist; the ly-
sine analogues have their proponents. Other alternatives, such
as recombinant Factor VIIa (NovoSeven, Novo Nordisk,
Bagsvaerd, Denmark), prothrombotic by definition, may not
be as palatable from an economic or side effect point of view.
Controversy will always exist within the medical and sci-
entific community. This particular controversy has placed494 The Journal of Thoracic and Cardiovascular Surgery c Masome surgeons in a precarious situation: Do we stop using
aprotinin in high-risk cases (eg, the Jehovah Witness, left
ventricular assist device implantation, complex aortic sur-
gery) knowing that bleeding may be a problem? Similarly,
do we continue using aprotinin for the same patients knowing
that there may be added risk? Do we wait for the results of
a single study (ie, BART) despite the volume of studies pre-
ceding BART?And if the BART results prove to be inconclu-
sive, do we resume using aprotinin until the next negative
study appears? In the face of conflicting ‘‘facts’’ and numer-
ous opinions, it seems that the best course of action remains to
adhere to individual responsibilities. The DSMB should con-
tinue to be vigilant in attempting to detect thresholds of differ-
ences in blinded studies; investigators should continue to try
and dissect differences that appear in trials; and clinicians
should continue to offer what they consider the standard of
care to their patients.
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